Next, we evaluated the synergistic anti-tumor effect of nigericin with anti-PD-1 antibody in the 4T1 xenograft model, which included relatively cold tumors and was resistant to immune checkpoint inhibitor treatment due to a lack of T cell infiltration and activation [43,44]. This evidence concerns the gene PDCD1 and neoplasm.